AtriCure, Inc. reported $570M of revenue over the trailing twelve months, +14% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $570M (to Q2 2026). Net income: $11M, trailing twelve months to Q2 2026. Free cash flow: $53M, trailing twelve months to Q2 2026. Operating margin: 2.1%, trailing twelve months to Q2 2026.

ATRCAtriCure, Inc.

Healthcare

$55.80+53% 1Y

$55.80

$25.8652 weeks$60.73

ATRC as reported

AtriCure, Inc. reported $570M of revenue over the trailing twelve months, +14% on the year before. 11 reported series are charted on this page, each one as filed.

$570M

Revenue, trailing twelve months · to Q2 2026 · +14% against the twelve months before

Net income: $11M
Net income · −129% year on year · trailing twelve months to Q2 2026
Free cash flow: $53M
Free cash flow · +110% year on year · trailing twelve months to Q2 2026
Operating margin: 2.1%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ATRC, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$570M	+14%	Q2 2026
Net income	$11M	−129%	Q2 2026
EPS	$0.21	−127%	Q2 2026
Gross margin	76%	n/a	Q2 2026
Operating margin	2.1%	n/a	Q2 2026
Net margin	1.7%	n/a	Q2 2026
ROE	−1.8%	n/a	Q2 2026
ROA	−1.4%	n/a	Q2 2026
ROIC	−1.3%	n/a	Q2 2026
Free cash flow	$53M	+110%	Q2 2026
P/E	266	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.